



Referenties bij MAGMA 2-2013

Gereviseerde NHG-Standaard Maagklachten ook als *app* beschikbaar, p. 36–37

Mattijs Numans, Niek de Wit, Jos Dirven, Corien Heemstra-Borst, Gerard Hurenkamp, Mieke Scheele, Jako Burgers, Roeland Geijer, Egbert de Jongh. 'NHG-Standaard Maagklachten (tweede herziening)'. *Huisarts en Wetenschap*, jaargang 2013;1:26–35.

Endoscopiecapaciteit in Nederland, p. 45

1. Van Turenhout ST, Terhaar sive Droste JS, Meijer GA, Masclée AA, Mulder CJ. Anticipating implementation of colorectal cancer screening in The Netherlands: a nation wide survey on endoscopic supply and demand. *BMC cancer* 2012, 12:46.
2. Protocol voor de toelating en auditing van coloscopiecentra en endoscopisten. Nov 2012 (versie 2.0).

Domperidon: een dodelijk placebo? p. 50–51

1. Wilde AMM, Geneesmiddelen het lange QT interval. *Geneesmiddelenbulletin* 2002;3:27–32
2. Straus SM, et al. Non-cardiac QTc-prolonging drugs and the risk of sudden cardiac death. *Eur Heart J* 2005;26:2007–12.
3. Van Noord Ch, et al. Domperidone and ventricular arrhythmia or sudden cardiac death: a population-bases case controle study in the Netherlands. *Drug safety* 2010;33:1003–14.

Reactivatie hepatitis B leidt tot onnodige morbiditeit en mortaliteit, p. 52

1. Hahne SJ, Veldhuijzen IK, Wiessing L, Lim TA, Salminen M, Laar M. Infection with hepatitis B and C virus in Europe: a systematic review of prevalence and cost-effectiveness of screening. *BMC Infect Dis* 2013. Apr 18;13(1):181.
2. Hoofnagle JH. Reactivation of hepatitis B. *Hepatology* 2009. May;49 (5 Suppl):S156-65.
3. Lok AS, Liang RH, Chiu EK, Wong KL, Chan TK, Todd D. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. *Gastroenterology* 1991. Jan;100(1):182-8.
4. Flowers MA, Heathcote J, Wanless IR, Sherman M, Reynolds WJ, Cameron RG, et al. Fulminant hepatitis as a consequence of reactivation of hepatitis B virus infection after discontinuation of low-dose methotrexate therapy. *Ann Intern Med* 1990. Mar 1;112(5):381-2.
5. Ramsoekh D, Metselaar HJ, de Man RA. [Reactivation of hepatitis B infection due to glucocorticoids] Reactivatie van hepatitis B door glucocorticoiden. *NTvG* 2011. 155(50):A3710.
6. Michel M, Duvoux C, Hezode C, Cherqui D. Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset still's disease. *J Rheumatol* 2003. Jul;30(7):1624-5.
7. Yeo W, Chan TC, Leung NW, Lam WY, Mo FK, Chu MT, et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. *J Clin Oncol* 2009. Feb 1;27(4):605-11.
8. Takkenberg RB, Zaaijer HL, ten Cate DF, Biemond BJ, Jansen PL, Reesink HW. [Reactivation of hepatitis B virus in patients with hematological neoplasms] Reactivatie van het hepatitis B-virus bij patienten met een hematologische maligniteit. *NTvG* 2009. May 9;153(19):926-31.



9. Loomba R, Rowley A, Wesley R, Liang TJ, Hoofnagle JH, Pucino F, et al. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. *Ann Intern Med* 2008. Apr 1;148(7):519-28.
10. Katz LH, Fraser A, Gafter-Gvili A, Leibovici L, Tur-Kaspa R. Lamivudine prevents reactivation of hepatitis B and reduces mortality in immunosuppressed patients: systematic review and meta-analysis. *J Viral Hepat* 2008. Feb;15(2):89-102.
11. Zurawska U, Hicks LK, Woo G, Bell CM, Krahn M, Chan KK, et al. Hepatitis B virus screening before chemotherapy for lymphoma: a cost-effectiveness analysis. *J Clin Oncol* 2012. Sep 10;30(26):3167-73.
12. Marcellin P, Gane E, Buti M, Afdhal N, Sievert W, Jacobson IM, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. *Lancet* 2013. Feb 9;381(9865):468-75.
13. Chang TT, Lai CL, Kew Yoon S, Lee SS, Coelho HS, Carrilho FJ, et al. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. *Hepatology* 2010. Feb;51(2):422-30.
14. European Association For The Study Of The L. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. *J Hepatol* 2012. Jul;57(1):167-85.

Waarschuwing: propranolol bij refractaire ascites, p.

1. Sersté T, Melot C, Francoz C et al. Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites. *Hepatology* 2010;52:1017–22.
2. Sersté T, Francoz C, Durand F et al. Beta-blockers cause paracentesis induced circulatory dysfunction in patients with cirrhosis and refractory ascites: a cross-over study. *J Hepatol* 2011;55:794–9.
3. Angeli A. β -Blockers and refractory ascites in cirrhosis: the message of a team of true scientists. *J Hepatol* 2011;55:743–4 (Editorial).

CASUÏSTIEK – Unilateraal pleuravocht, p. 63

1. Ali T, Srinivasan N, Le V, et al. Pancreaticopleural fistula. *Pancreas*.2009; 28:e26-31.
2. Machado NO. Pancreaticopleural fistula: Revisited. *Diagn Ther Endosc*. 2012; 2012:815476.

CASUÏSTIEK – Een late metastase, p. 65

1. Gardini A, Morgagni P, Milandri C, et al. Pancreatic resection for metastases from renal cancer: long term outcome after surgery and immunotherapy approach – single center experience. *HepatoGastroenterology* 2012;59(115):687–90.
2. Ballarin R, Spaggiari M, Cautero N, et al. Pancreatic metastases from renal cell carcinoma: the state of the art. *World J Gastroenterol* 2011;17(43):4747–56.
3. Sotiropoulos GC, Lang H, Liu C, et al. Surgical treatment of pancreatic metastases of renal cell carcinoma. *JOP* 2005;8;6(4):339–43.
4. Tanis PJ, van der Gaag NA, Busch OR, et al. Systematic review of pancreatic surgery for metastatic renal cell carcinoma. *Br J Surg* 2009;96(6):579–92.